



WESTMINSTER
HEALTH FORUM

The future of biosimilars in the UK - innovation, regulation and increasing uptake 18th October 2018

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Daniel Zeichner MP , Vice-Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	6
<u>'Can we balance the potential biosimilars NHS financial windfall with improved patient access - and ensure a sustainable market for the UK?'</u>	
Angela McFarlane , Market Development Director, IQVIA (<i>text to be submitted</i>)	7
<u>Realising the potential of biosimilars - research, innovation and intellectual property</u>	
Kavya Gopal , Head of Specialty, Sandoz and Chair, British Biosimilars Association (<i>transcript</i>)	8
Marjan Noor , Partner, Allen & Overy (<i>transcript</i>)	11
Dr James Rose , Head of Clinical Innovation Adoption, Oxford Academic Health Science Network (<i>text to be submitted</i>)	13
Questions and comments from the floor with Angela McFarlane , Market Development Director, IQVIA (<i>transcript</i>)	14
<u>Session Chair's closing remarks</u>	
Daniel Zeichner MP , Vice-Chair, All-Party Parliamentary Group for Life Sciences (<i>transcript</i>)	24
<u>Session Chair's opening remarks</u>	
Chris Green MP , Chair, All-Party Parliamentary Group on Medical Research (<i>transcript</i>)	26
<u>Bringing biosimilars to the marketplace - ensuring the effectiveness of new medicines</u>	
Theo Christie , Business Development Manager, NIHR Clinical Research Network (<i>text to be submitted</i>)	27
<u>Increasing the uptake of biosimilars - engaging clinicians, developing local commissioning frameworks and supporting patient choice</u>	
Julie Wood , Chief Executive, NHS Clinical Commissioners (<i>transcript</i>)	28
Dr Martin Perry , Consultant Physician & Rheumatologist, NHS Greater Glasgow and Clyde (<i>transcript</i>)	31
Jatinder Harchowal , Chief Pharmacist, The Royal Marsden NHS Foundation Trust (<i>transcript</i>)	33
Dr Alasdair Rankin , Director of Research and Patient Experience, Bloodwise (<i>transcript</i>)	37
Questions and comments from the floor with Theo Christie , Business Development Manager, NIHR Clinical Research Network (<i>transcript</i>)	40
<u>Priorities for the regulation of biosimilars - responding to new entrants in the market</u>	
Dr Christian Schneider , Director, National Institute for Biological Standards and Control, Medicines and Healthcare Products Regulatory Agency (<i>transcript</i>)	50
Questions and comments from the floor (<i>transcript</i>)	55
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Chris Green MP , Chair, All-Party Parliamentary Group on Medical Research (<i>transcript</i>)	57
Stephanie Thomson , Senior Researcher, Westminster Health Forum (<i>transcript</i>)	58
<u>List of Delegates Registered for Seminar</u>	59
<u>Contributor Biographies</u>	63
<u>About the Core Sponsors of the Westminster Health Forum</u>	66

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum Keynote Seminar: The future of biosimilars in the UK - innovation, regulation and increasing uptake held on 18th October 2018. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796

F: 01344 420121

publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder

Chris Whitehouse